Clinical Briefings

Clinical Briefings™: The Cutting Edge of Sleep Science: Emerging Treatments in Insomnia

Medical Crossfire®

Medical Crossfire®: Transitioning from Pediatric to Adult SMA Care Teams: How Do We Optimize Outcomes as Patients Age?

Provider and Caregiver Connection: Understanding and Addressing the Effects of Pseudobulbar Affect on Patients' QoL

Clinical Briefings™: Examining the Role of CGRPs for the Treatment of Cluster Headaches

Online Activities

Amyotrophic Lateral Sclerosis: An Evaluation of Current Treatments and Multidisciplinary Approaches to Care

Advances In&trade;

Advances in™ Treating Alzheimer Disease: An Update on the Search for Disease-Modifying Therapies

Clinical ShowCase

Clinical ShowCase: Next Best Steps in Managing EDS in OSA

Clinical Consultations™

Clinical Consultations™: Closing the Gap in Early Identification and Treatment of SMA

Advances In™ Amyotrophic Lateral Sclerosis &mdash; Developments in SOD1 Targeting

Clinical Consultations: An Expert Discussion on Immunoglobulin Therapy in CIDP &mdash; Optimizing Treatment to Improve Quality of Life

Enduring Activity

3rd Annual Advanced Practice Collaborative

Community Practice Connections™

Community Practice Connections™: 2nd Annual International Congress on the Future of Neurology®

<h2 style="text-align:center">Current and Emerging Treatment Strategies for Cluster Seizures: A Primer for Managed Care Pharmacists</h2>

<div style="text-align:center">Live Free Accredited Webinar! 
March 31, 2021 | 6:00 PM ET and 8:00 PM ET 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Neurelis Inc.</div>
 
Faculty Presenter 
 
Kristy Greene, PharmD, BCPS, BCCCP 
Clinical Pharmacist Specialist 
Neuroscience Critical Care Medicine 
Emory University Hospital Midtown 
Atlanta, Georgia 
 
Clinical Assistant Professor 
Philadelphia College of Osteopathic Medicine, School of Pharmacy 
Suwanee, Georgia 
&nbsp;
<div>
<hr /></div>
 
Program Description 
 
With 150,000 new diagnoses each year, epilepsy is the fourth most common neurologic condition in the United States. Seizures negatively affect patients&rsquo; ability to perform daily functions, which consequentially impacts their socioeconomic status and mental health. These effects are exacerbated by cluster seizures, or multiple seizures within a short time, which may occur in patients who have drug-resistant epilepsy. In order to prevent cluster seizures and give patients access to more effective options, managed care pharmacists must be familiar with emerging rescue treatments administered through alternative routes. Ensuring that patients have access to effective rescue therapy remains a critical aspect of management, and managed care pharmacists must consider development of coverage criteria to ensure appropriate utilization of these agents. Pharmacists in managed care settings provide an important role in selecting drug therapy, monitoring patients, and addressing unmet medical needs, and they must remain informed about treatment options and guidelines. 
 
Target Audience:&nbsp; Managed care pharmacists 
Type of Activity:&nbsp;Application 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine factors that influence the classification of seizures and the burden of disease of cluster seizures</li>
	<li>Explain current and emerging rescue treatment options for patients experiencing cluster seizures</li>
	<li>Identify the role of managed care pharmacists in the development and implementation of utilization management of newer rescue treatment options for cluster seizures</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-078-L01-P. The activity is available for CE credit through May 31, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Kristy Greene, PharmD, BCPS, BCCCP, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Current and Emerging Treatment Strategies for Cluster Seizures: A Primer for Managed Care Pharmacists

<h2 style="text-align:center">Amyotrophic Lateral Sclerosis: Managed Care Considerations and Updates on Recent Clinical and Real-World Data</h2>

<div style="text-align:center">An American Journal of Managed Care&reg; Program 
 
1.5-Hour On-Demand Payer Forum 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Mitsubishi Tanabe Pharma America, Inc.</div>
 
Faculty Presenters 
 
Moderator 
Gary M. Owens, MD 
President, Gary Owens Associates 
Ocean View, Delaware 
 
Richard Bedlack, MD, PhD 
Professor of Neurology, Director of ALS Clinic 
Duke University Department of Neurology 
Durham, North Carolina 
 
Sarah Dehoney, PharmD, BCPS 
Clinical Pharmacist 
Department of Neurology 
University of Utah 
Salt Lake City, Utah 
 
Khalid M. Kamal, MPharm, PhD 
Professor and Chair 
Department of Pharmaceutical Systems and Policy 
Health Sciences Center 
West Virginia University School of Pharmacy 
Morgantown, West Virginia 
 
Medical Writer 
C. Andrew Kistler, MD, PharmD 
Clinical Instructor 
Division of Gastroenterology and Hepatology 
Thomas Jefferson University Hospital 
Philadelphia, Pennsylvania 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Amyotrophic lateral sclerosis (ALS) is a devastating and debilitating disease, presenting with rapid decline in upper and lower motor neurons as well as difficulties swallowing, speaking, and, eventually, breathing. Due to the number of body functions that become compromised as ALS progresses, patients and caregivers must see a number of different specialists, all of whom must be integrated with the multidisciplinary care team. The foremost challenge in ALS is delayed diagnosis and initiation of treatment. Although there is no cure for ALS, 2 drugs are currently FDA approved to slow disease progression, and others in development show promise to stem or reverse disease course. However, the cost of care and potentially curative therapies can accrue to well over a million dollars for patients during the disease course. This discussion among panelists will examine real-world cost and resource utilization data for approved ALS treatments. As more disease-modifying drugs emerge for consideration of ALS treatment, managed care professionals must evaluate benefits versus costs and establish guidelines to make therapy options available for patients. 
 
Target audience:&nbsp;Managed care pharmacists, specialty pharmacists, payers, managed care professionals, pharmacy benefit managers 
Type of activity:&nbsp;Application 
Release date: January 29, 2021 
Expiration date: January 29, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Examine the progressive nature of amyotrophic lateral sclerosis (ALS) and the prognosis of disease based on stage and patient factors.</li>
	<li>Explore recent real-world and clinical data for disease-modifying agents in the management of ALS.&nbsp;</li>
	<li>Use updated data when developing evidence-based pathways for the care of patients with ALS.</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-007-H01-P. The activity is available for CE credit through January 29, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Gary M. Owens, MD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: Horizon Pharmaceuticals, Intersect ENT, Novartis, Regeneron, Sanofi, Eli Lilly</li>
</ul>
 
Richard Bedlack, MD, PhD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Grant/Research Support: ALS Association, Healey Center, MediciNova, Orion, Ultragenyx</li>
	<li>Consultant: Alexion, ALS Association, Biogen, Brainstorm, Mallinckrodt, MT Pharma America, New Biotic, Woolsey Pharma</li>
</ul>
 
Khalid M. Kamal, MPharm, PhD, and Sarah Dehoney, PharmD, BCPS, have no relevant financial relationships with commercial interests to disclose. 
 
C. Andrew Kistler, MD, PharmD, has no relevant financial relationships with commercial interests to disclose. 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Ann Marciano; Brianna Schauer, MBA, PMP; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Disclosure Policy 
According to the disclosure policy of&nbsp;The American Journal of Managed Care&reg;&nbsp;and&nbsp;Pharmacy Times&nbsp;Continuing Education&trade;, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. 
 
Disclosure of Unapproved/Off-Label Use 
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products. 
 
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient&rsquo;s medical condition. 
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of&nbsp;The American Journal of Managed Care&reg;,&nbsp;Pharmacy Times&nbsp;Continuing Education&trade;, or any of the companies that provided commercial support for this CE activity. 
 
Signed disclosures are on file at the office of&nbsp;The American Journal of Managed Care&reg;, Cranbury, New Jersey. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Amyotrophic Lateral Sclerosis: Managed Care Considerations and Updates on Recent Clinical and Real-World Data

<h2 style="text-align:center">Achieving High-Quality Patient Outcomes in Spinal Muscular Atrophy: A Review of New Data and Managed Care Strategies</h2>

<div style="text-align:center">An American Journal of Managed Care&reg; Supplement 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Biogen.</div>
 
Faculty 
 
Elizabeth Bisaccia, PharmD, BCPPS 
Clinical Pharmacy Specialist 
Rush University Medical Center 
Chicago, Illinois 
 
Alan D. Pannier, PharmD, MBA 
Head of Clinical Services 
SmithRx 
Salt Lake City, Utah 
 
Medical Writing &amp; Editorial Support 
 
Brittany Hoffmann-Eubanks, PharmD, MBA 
Founder and CEO 
Banner Medical LLC 
Frankfort, Illinois 
 
Andrew Abe, PharmD 
Medical Writer 
Honolulu, Hawaii 
&nbsp;
<hr /> 
Program Description 
It is estimated that about one in 65 people are carriers of the gene mutation for spinal muscular atrophy (SMA), which causes degeneration of motor neurons and progressive muscle weakness affecting patients&rsquo; ability to move, swallow, and breathe. The rapid progression of SMA and high rate of mortality have contributed to its designation as a recommended condition for which all newborns should receive screening. The majority of patients with SMA present with signs and symptoms by 3 months of age, but symptom onset can vary according to SMA type, thus affecting treatment decisions and making early diagnosis and treatment initiation imperative. Previously, management of SMA consisted primarily of supportive care with specialized equipment, such as ventilators and feeding tubes, physical and occupational therapy, and other expert care to maintain patient quality of life, with astronomical associated costs. However, use of disease-modifying therapies has the potential to change existing treatment protocols, normalize development, and increase survival, especially for patients in whom a diagnosis was received early. These therapies are also associated with high costs and are often subject to extensive barriers to access. To balance the costs of treatment with improvement of patient outcomes, managed care professionals and pharmacists must establish a framework for evaluating newly approved therapies and expediting the use of these agents in the treatment of SMA. 
 
Target audience: Managed care pharmacists 
Activity type: Application 
Release date: January 29, 2021 
Expiration date:&nbsp; February 15, 2022 
Estimated time to complete activity: 2 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, the participant will be able to:

<ul>
	<li>Determine gold standards for treating spinal muscular atrophy (SMA) including updates to the 2020 revised recommendations.</li>
	<li>Use the most up-to-date clinical data of approved therapies to aid in advancing treatment options and patient-specific protocols for SMA.</li>
	<li>Employ strategies that allow access to patient-specific treatment protocols and the potential opportunities to offset costs in SMA.</li>
</ul>
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" /> 
Pharmacy Times Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hour (0.20 CEU) under the ACPE universal activity number 0290-0000-21-022-H01-P. The activity is available for CE credit through February 15, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, read the online article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Faculty 
 
Elizabeth Bisaccia, PharmD, BCPPS and Alan D. Pannier, PharmD, MBA, have no relevant financial relationships with commercial interests to disclose. 
 
Medical Writing &amp; Editorial Support Disclosures 
 
Brittany Hoffmann-Eubanks, PharmD, MBA, and Andrew Abe, PharmD, have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Disclosure Policy 
According to the disclosure policy of&nbsp;The American Journal of Managed Care&reg;&nbsp;and&nbsp;Pharmacy Times&nbsp;Continuing Education&trade;, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. 
 
Disclosure of Unapproved/Off-Label Use 
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products. 
 
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient&rsquo;s medical condition. 
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of&nbsp;The American Journal of Managed Care&reg;,&nbsp;Pharmacy Times&nbsp;Continuing Education&trade;, or any of the companies that provided commercial support for this CE activity. 
 
Signed disclosures are on file at the office of&nbsp;The American Journal of Managed Care&reg;, Cranbury, New Jersey. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Achieving High-Quality Patient Outcomes in Spinal Muscular Atrophy: A Review of New Data and Managed Care Strategies

<h2 style="text-align:center">Opportunities to Optimize Care in Pulmonary Arterial Hypertension</h2>

<div style="text-align:center">Live Free Accredited Webinar! 
Thursday, April 22, 2021, at 6:00 PM and 8:00 PM ET 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Actelion Pharmaceuticals US, Inc.</div>
 
Faculty Presenter 
 
Kristen T. Pogue, PharmD, BCCP 
Clinical Pharmacy Specialist, Cardiology 
Michigan Medicine 
 
Clinical Associate Professor 
University of Michigan College of Pharmacy 
 
Residency Program Director 
PGY2 Cardiology Pharmacy Residency 
Michigan Medicine 
Ann Arbor, Michigan 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
Program Description 
Over the past decade, treatment approaches for pulmonary arterial hypertension (PAH) have evolved, with efforts now focusing on providing earlier treatment to slow clinical deterioration. Goal-oriented therapy is a treatment strategy that also uses multiple prognostic indicators as treatment targets, with additional therapy considered when targets are not met. Delivery of medical care to patients with PAH is a complex undertaking that requires a multidisciplinary team with specialized expertise. As more pharmacologic therapies for PAH with unique mechanisms of action are approved, combination therapy that targets more than one pathogenicity of PAH may provide superior benefit to monotherapy, and coordination of care will become more crucial in managing PAH. However, with polypharmacy, pharmacists must balance the increased benefits with increased risks, including drug interactions, increase in medication burden that may decrease adherence, and risk of catheter-related infections and pump malfunctions for drugs that are administered via intravenous or subcutaneous injection. In addition, PAH drug therapy has a high rate of adverse effects that require monitoring and have been linked to poor medical adherence. As new agents for PAH emerge, it is crucial that health-system pharmacists understand the adverse effect profile and risks of interactions to ensure the benefit of combination PAH therapy outweighs the risks. 
 
Target audience: Health-system and specialty pharmacists 
Type of activity:&nbsp;Application 
Fee:&nbsp;Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:

<ul>
	<li>Identify pulmonary arterial hypertension (PAH) by WHO Functional Class and describe prognostic treatment goals (eg, low risk)</li>
	<li>Examine different treatment paradigms implemented to improve patient care and treatment outcomes in PAH</li>
	<li>Compare the current and emerging therapies for PAH treatment, including their clinical efficacy, safety, drug interactions, and administration</li>
	<li>Outline health-system pharmacist activities that can improve multidisciplinary care and improve quality of life for patients with PAH</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-014-L01-P. The activity is available for CE credit through June 22, 2021. 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Disclosures 
 
Faculty 
 
Kristen T. Pogue, PharmD, BCCP, has the following relevant financial relationships with commercial interests to disclose: 
Consultant: Merck, Shionogi, Qpex, Entasis, Utility Therapeutics (spouse) 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by&nbsp;PTCE.&nbsp;PTCE reserves the right to cancel an event without notice.&nbsp;PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Opportunities to Optimize Care in Pulmonary Arterial Hypertension

<h2 style="text-align:center">Parkinson Disease: A Review of Treatment Guidelines, Healthcare Utilization Data, and Emerging Therapies</h2>

<div style="text-align:center">A 1-hour on-demand webinar. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Biogen Inc.</div>
 
Faculty Presenter 
 
Winston Wong, PharmD 
President 
W-Squared Group 
Longboat Key, Florida 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Approximately 60,000 Americans are diagnosed with Parkinson disease (PD) each year, with an economic burden of at least $14 billion that is expected to double by 2040. Several key challenges and unmet medical needs exist in the PD treatment landscape. Guidelines addressing treatment of PD with and without motor symptom involvement were last published in 2006 and 2010 by the American Academy of Neurology and have since been retired. As no disease-modifying therapies yet exist to address the underlying pathology of PD, decisions about when to initiate treatment are often debated and represent a major limitation for pharmacists and managed care professionals. Current treatment options are also associated with frequent adverse effects that may be dose-limiting for patients, further impairing tolerability and diminishing patient quality of life. Polypharmacy with adjunctive medications is often required and compounds direct medical costs. Managed care professionals and pharmacists should keep abreast of the status of ongoing research for therapeutic agents for PD with the potential to prevent complications that contribute to increased healthcare resource utilization and poor clinical outcomes. This activity will provide a review of the current treatment landscape of PD and an in-depth overview of emerging disease-modifying therapies under development. 
 
Target audience:&nbsp;Managed care pharmacists 
Type of activity:&nbsp;Application 
Release date: November 18, 2020 
Expiration date: November 18, 2021 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Examine the rising prevalence of Parkinson disease including the clinical and economic burden</li>
	<li>Identify the current standard of care for Parkinson disease including clinical trial data for new and emerging treatments</li>
	<li>Explore the place in therapy and potential impact of new and emerging treatments for Parkinson disease</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-371-H01-P. The activity is available for CE credit through November 18, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Winston Wong, PharmD, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Parkinson Disease: A Review of Treatment Guidelines, Healthcare Utilization Data, and Emerging Therapies

<h2 style="text-align:center">The Pharmacoeconomic Burden of Insomnia:&nbsp;Current Treatment Challenges and Updates on Safe and&nbsp;Efficacious Options</h2>

<div style="text-align:center">1.5-hour On-demand CE Webcast 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Eisai.</div>
 
Faculty Presenters 
 
Douglas S. Burgoyne, PharmD, FAMCP 
Associate Adjunct Professor 
Department of Pharmacotherapy 
University of Utah College of Pharmacy 
Salt Lake City, Utah 
 
Julie A. Dopheide, PharmD, BCPP, FASHP 
Professor of Clinical Pharmacy 
University of Southern California School of Pharmacy and Keck School of Medicine 
Los Angeles, California 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
In 2014, the classification of insomnia as a comorbid designation was revised, and it is now considered a disorder defined as difficulty with the initiation or maintenance of sleep. About 1 in 5 cases of insomnia becomes chronic and can persist for years, making the economic and quality of life burdens of insomnia significant, especially on vulnerable patient groups and those with coexisting medical or psychiatric disorders. Managed care professionals must converse with clinicians to improve knowledge and use of guideline recommendations and the role of cognitive behavioral therapy for insomnia (CBT-I) in clinical practice. Likewise, pharmacists involved in the treatment and management of patients with insomnia must accurately explain the risks and benefits of currently available insomnia drugs as well as emerging treatment approaches. The up-to-date information explored in this program will help managed care professionals incorporate costeffective pharmaceutical care and protocols into practice to provide high-quality care to patients with insomnia. 
 
Target audience:&nbsp;Specialty and managed care pharmacists, managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in or involved in the care of patients with insomnia. 
Type of activity:&nbsp;Application 
Release date: November 3, 2020 
Expiration date:&nbsp;November 3, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Characterize the pathophysiology, epidemiology, and disease burden of insomnia including the impact on quality of life in vulnerable patient groups</li>
	<li>Identify appropriate pharmacotherapy for insomnia based on guideline recommendations, drug efficacy and safety profiles, and patient factors</li>
	<li>Examine the economic burden of insomnia and impact of available treatment options, including effects on vulnerable patient groups</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-330-H01-P. The activity is available for CE credit through November 3, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
Douglas S. Burgoyne, PharmD, FAMCP, and Julie A. Dopheide, PharmD, BCPP, FASHP, have no relevant financial relationships with commercial interests to disclose: 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

The Pharmacoeconomic Burden of Insomnia: Current Treatment Challenges and Updates on Safe and Efficacious Options

<h2 style="text-align:center">Parkinson Disease: A Review of Guidelines, Updates,&nbsp;and Treatment Advances</h2>

<div style="text-align:center">1.5-hour On-demand CE Webcast 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Acadia Pharmaceuticals and Acorda Therapeutics.</div>
 
Faculty Presenters 
 
Erica Marini, PharmD, MS, BCPS 
Clinical Pharmacist, Neurology 
University of Utah Health 
Salt Lake City, Utah 
 
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP 
Senior Director, Clinical Analytics 
WellDyne 
Tampa, Florida 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
In recent years, there have been numerous advances in therapies for Parkinson disease (PD), but guidelines for treatment are far behind. The progressive impairment in motor functioning and worsening symptoms restricting autonomic, sensory, and neuropsychiatric functions cause significant burdens on patients&rsquo; quality of life. Although dopaminergic agents are effective for management of motor symptoms associated with PD, they do not provide neuroprotective effects or alter progression of the disease. Such agents are also associated with frequent dose-limiting adverse effects that warrant the use of adjunctive medications and compound direct medical costs. This activity will review ongoing clinical trial data for agents targeting the &alpha;-synuclein pathology associated with PD as well as new formulations with the potential to minimize motor-related complications. In the absence of long-term evidence for neuroprotection, managed care pharmacists should be able to address patient expectations regarding appropriate drug therapy, proper medication use and dosage, and current limitations of the medications available for PD. 
 
Target audience:&nbsp;Specialty and managed care pharmacists, managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in the scientific advances of or involved in the care of patients with Parkinson disease. 
Type of activity:&nbsp;Application 
Release date: October 30, 2020 
Expiration date: October 30, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Examine diagnostic considerations, approaches to therapy, and the quality of life burden of patients and caregivers in Parkinson disease (PD)</li>
	<li>Analyze current treatments and guidelines for PD as well as the clinical data to support new and emerging treatments</li>
	<li>Explore management strategies when considering access to therapies for PD</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-329-H01-P. The activity is available for CE credit through October 30, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
Erica Marini, PharmD, MS, BCPS, and Patty Taddei-Allen, PharmD, MBA, have no relevant financial relationships with commercial interests to disclose: 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Parkinson Disease: A Review of Guidelines, Updates, and Treatment Advances

<h2 style="text-align:center">Addressing Clinical and Economic Burden in Alzheimer Disease: Examining New and Emerging Therapies and Optimizing Patient Care, an AMCP Nexus Satellite Symposium, featuring a Caregiver Perspective</h2>

<div style="text-align:center">1.5-hour On-demand CE Webcast 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Biogen Inc.</div>
 
Faculty Presenters 
 
Gary W. Small, MD 
Professor of Psychiatry and Biobehavioral Sciences, Parlow-Solomon Professor on Aging 
Director, Division of Geriatric Psychiatry; Director, UCLA Longevity Center 
UCLA Semel Institute for Neuroscience and Human Behavior 
David Geffen School of Medicine at UCLA 
Los Angeles, California 
 
Winston Wong, PharmD 
President 
W-Squared Group 
Longboat Key, Florida 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Alzheimer disease (AD) is the sixth leading cause of death and the most common etiology for dementia. The progressive nature of AD causes a significant burden to patients, caregivers, and the public health system as just over half of patients who receive a diagnosis of AD initiate treatment and even fewer continue with therapy. Although beta-amyloid inhibitors and monoclonal antibodies have the potential to change the AD treatment landscape, a significant limitation of pharmacologic treatment is that current medications only succeed in providing temporary symptomatic relief, and there are no approved medications that alter the course of AD. Because AD is a disease more commonly diagnosed in older adults and affects cognition, pharmacists have important roles in communicating with caregivers about the patient&rsquo;s existing comorbidities and medication profile to prevent drug interactions. Implementation of recently released guidelines for the diagnosis and evaluation of AD can improve multidisciplinary care and quality of life for patients with AD as well as reduce caregiver burden. This activity will detail the role of the pharmacist in collaboration with managed care professionals and clinicians to promote drug utilization strategies that can be initiated early in the treatment course of AD. 
 
Target Audience:&nbsp;Specialty and managed care pharmacists, managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in the scientific advances of treating or involved in the care of patients with Alzheimer disease. 
 
Type of Activity:&nbsp;Application 
Release date: October 30, 2020 
Expiration date: October 30, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives: 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Explore the impact of Alzheimer disease (AD) as it relates to progression, value of early diagnosis, associated comorbidities, and effect on patients and caregivers</li>
	<li>Analyze current and emerging data for new therapeutic targets for the pharmacologic treatment of AD</li>
	<li>Examine the economic burden of AD and strategies to improve outcomes among patients with AD in a managed care population</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-337-H01-P. The activity is available for CE credit through October 30, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Gary W. Small, MD, has the following relevant financial relationships with commercial interests to disclose: 
Grant/Research Support: Wonderful Co. 
Consultant: ARP, Acadia, Avanir, Genentech, Handok, Herbalife, Medscape, RB Health, Roche, Theravalues, WebMD 
Speakers Bureau: Acadia 
Stock/Shareholder: Ceremark Pharma, LLC 
Spouse: Co-founder of Ceremark Pharma, LLC 
 
Winston Wong, PharmD, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Addressing Clinical and Economic Burden in Alzheimer Disease: Examining New and Emerging Therapies and Optimizing Patient Care, an AMCP Nexus Satellite Symposium, featuring a Caregiver Perspective

<h2 style="text-align:center">Spinal Muscular Atrophy: Updates in Clinical Trial Data and What Managed Care Professionals Need to Know, featuring a Patient Perspective </h2>

<div style="text-align:center">1.5-hour Webcast 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Biogen Inc. and Genentech, a member of the Roche Group. </div>
 
Faculty Presenters 
 
Alan Pannier, PharmD, MBA 
Head of Clinical Services 
SmithRx 
Salt Lake City, Utah 
 
Crystal Proud, MD 
Neuromuscular Neurologist 
Children&rsquo;s Hospital of the King&rsquo;s Daughters 
Children&rsquo;s Specialty Group 
Norfolk, Virginia 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Approximately 9000 people in the United States are diagnosed with spinal muscular atrophy (SMA), and 1 in 50 people are carriers of the disease. Due to a high mortality rate associated with early-onset disease and different SMA type classifications, early intervention with genetic and newborn screening approaches is essential to predict severity and individualize patient treatment to control progression rates. Management of SMA has consisted primarily of supportive care to slow or prevent respiratory failure, nutritional compromise, and joint contractures. Patients with SMA who require supportive care for breathing difficulties, difficulty feeding and swallowing, and specialized occupational therapy incur exorbitant financial burden. Recently approved disease-modifying therapies have the potential to change the treatment landscape of SMA. As new data on the safety and efficacy of emerging treatments for SMA emerge, it is imperative that managed care professionals make informed decisions for optimal care of patients with this disease. 
 
Target audience:&nbsp;Managed care, payer, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professionals who are interested in the management of spinal muscular atrophy. 
 
Type of activity:&nbsp;Application 
Release date: October 27, 2020 
Expiration date: October 27, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Characterize the pathogenesis of spinal muscular atrophy (SMA) including its clinical presentation, classifications, diagnosis, and the need for early intervention</li>
	<li>Examine current and emerging treatment options for SMA including updated clinical trial data</li>
	<li>Explore the current guidelines for SMA and managed care implications for incorporating SMA therapies into treatment</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-323-H01-P. The activity is available for CE credit through October 27, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Faculty 
Crystal Proud, MD, has the following financial relationships with commercial interests to disclose: 
Consultant: Biogen, AveXis 
Speakers Bureau: Biogen, AveXis 
 
Alan Pannier, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Ann Marciano; Shawna Wilker; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Spinal Muscular Atrophy: Updates in Clinical Trial Data and What Managed Care Professionals Need to Know, featuring a Patient Perspective

<h2 style="text-align:center">Secondary Progressive Multiple Sclerosis: Effective Management Strategies for Pharmacists </h2>

<div style="text-align:center">An on-demand CE webcast held in conjunction with the 2020 National Association of Specialty Pharmacy (NASP) Annual Meeting &amp; Expo 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by 
MJH Life Sciences&trade;, the parent company of Pharmacy Times&reg; and PTCE.</div>
 
Faculty Presenter 
 
Ryan Fuller, PharmD 
Clinical Pharmacy Specialist 
The Hospital of the University of Pennsylvania 
Philadelphia, Pennsylvania 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Multiple sclerosis (MS) can have extremely variable clinical presentation and staging that pharmacists must be familiar with to determine the most effective treatment approach to slow disease worsening, which is the primary goal of MS therapy. Approximately 85% to 90% of patients initially present with relapsing-remitting MS (RRMS, predominantly inflammatory), which then transitions to secondary progressive MS (SPMS, predominantly neurodegenerative). Although the development of disease-modifying therapies has aimed to delay the progressive disability associated with this disease, treatment options sometimes fail to elicit desired responses in many patients. To best provide continuity of care for patients with SPMS, specialty pharmacists need to monitor instances of treatment failure or nonadherence among patients to recommend alternative options as needed. Emerging treatment options for SPMS have unique administration, dosing, and safety considerations that specialty pharmacists must deliberate with the multidisciplinary team to enhance treatment and management strategies and improve overall quality of life of patients with MS.&nbsp; 
 
Target audience:&nbsp;Specialty pharmacists 
Type of activity:&nbsp;Application 
Release date: October 14, 2020 
Expiration date: October 14, 2021 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Express the etiology, pathophysiology, classification, and diagnosis of secondary progressive multiple sclerosis (SPMS)</li>
	<li>Analyze current treatment guidelines and the latest data on the efficacy and safety of approved pharmacologic treatments for SPMS</li>
	<li>Examine the role of the specialty pharmacist in the management of SPMS including optimization of care and patient education.</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-284-H01-P. The activity is available for CE credit through October 14, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
The following contributor has a relevant financial relationship with a commercial interest to disclose: 
 
Faculty 
Ryan Fuller, PharmD 
Consultant: Novartis advisory board 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, RPh, CHCP; Brianna Schauer, MBA; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Secondary Progressive Multiple Sclerosis: Effective Management Strategies for Pharmacists

<h2 style="text-align:center">Immunoglobulin Use in Chronic Inflammatory Demyelinating Polyneuropathy: A Discussion of Treatment and Management</h2>

<div style="text-align:center">Free On-Demand 3-Part Payer Forum With Device Demonstration Videos 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
CSL Behring.</div>
 
Click the links below to view the device demonstration videos: 
<a href="https://s3.amazonaws.com/ptce/_media/_videos/CIDP device video 1.mp4" target="_blank">Part 1</a> 
<a href="https://s3.amazonaws.com/ptce/_media/_videos/CIDP device video 2.mp4" target="_blank">Part 2</a> 
&nbsp;
<hr /> 
Faculty Presenters 
 
Ryan K. Bitton, PharmD, MBA 
Senior Director, Pharmacy Services 
Health Plan of Nevada 
Las Vegas, Nevada 
 
Elizabeth Duruz, RPh, CSP 
Director, Clinical Program Services, Pharmacy 
Diplomat Specialty Infusion Group 
Atlanta, Georgia 
 
Gary M. Owens, MD 
President, Gary Owens Associates, Inc 
Ocean View, Delaware 
 
Kelly Sandlian, RN 
Biological Infusion Nurse 
Noblesville, Indiana 
 
Nicholas J. Silvestri, MD 
Associate Professor of Neurology 
University at Buffalo Jacobs School of Medicine &amp; Biomedical Sciences 
Buffalo, New York 
 
Medical Writer 
 
C. Andrew Kistler, MD, PharmD 
Clinical Assistant Professor of Medicine 
Division of Gastroenterology and Hepatology 
Thomas Jefferson University Hospital 
Sidney Kimmel Medical College 
Philadelphia, Pennsylvania 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Patients with chronic inflammatory demyelinating polyneuropathy experience progressive weakness and reduced functioning of the extremities due to peripheral nerve damage. If left untreated, an estimated 30% of patients would eventually become wheelchair dependent. Expanding therapy options, including subcutaneous (SC) and intravenous (IV) immunoglobulin administration in CIDP treatment in maintaining disease stability have necessitated that pharmacists be able to navigate the intricacies of these therapies, including dosing schedules and infusion rates. The introduction of SCIG into CIDP treatment has created unique economic challenges and considerations of healthcare usage for managed care pharmacists. The different perspectives of the panelists in this discussion and accompanying device demonstration videos will equip managed care pharmacists with strategies to standardize management, decrease healthcare utilization and treatment burden, and optimize outcomes of patients with CIDP. 
 
Target Audience:&nbsp;Specialty and managed care pharmacists 
Type of Activity:&nbsp;Application 
Release date: September 30, 2020 
Expiration date: September 30, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Explore the journey of a patient with CIDP, from loss of function to treatment initiation and maintenance</li>
	<li>Analyze intravenous and subcutaneous immunoglobulin treatments, including safety, efficacy, dosing, and use</li>
	<li>Examine the economics and managed care implications of CIDP care coordination in inpatient and outpatient settings</li>
	<li>Illustrate the use of infusion pumps in outpatient settings</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-297-H01-P. The activity is available for CE credit through September 30, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Nicholas J. Silvestri, MD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: argenx, Alexion Pharmaceuticals</li>
</ul>
 
Gary M. Owens, MD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: Intersect ENT, Horizon Pharma, Novartis, Octave Biosciences, Eli Lilly</li>
	<li>Other Support: Patient Access Network Foundation</li>
</ul>
 
Elizabeth Duruz, RPh, CSP; C. Andrew Kistler, MD, PharmD; Kelly Sandlian, RN; and Ryan K. Bitton, PharmD, MBA, have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Immunoglobulin Use in Chronic Inflammatory Demyelinating Polyneuropathy: A Discussion of Treatment and Management

<h2 style="text-align:center">Myasthenia Gravis: Treatment Considerations for Specialty Pharmacists</h2>

<div style="text-align:center">A 1-hour on-demand webinar. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
CSL Behring.</div>
 
Faculty Presenter 
 
Leslie A. Hamilton, PharmD, FCCP, FCCM, BCPS, BCCCP 
Associate Professor of Clinical Pharmacy and Translational Science 
University of Tennessee Health Science Center College of Pharmacy 
Knoxville, Tennessee 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Myasthenia gravis (MG) is a rare and potentially life-threatening neuromuscular disease characterized by skeletal muscle weakness that worsens upon periods of exertion and improves with periods of rest. This weakness can be found in muscles controlling the eyes, face, neck, and limbs and can lead to double vision, difficulty chewing, swallowing, and holding up the head. If MG remains untreated, progressive muscle weakness can result in myasthenic crisis, which may require mechanical ventilation. Over the past several decades, the improvement of mechanical ventilation and better treatment options for MG have significantly improved prognosis. Successful treatment involves creating a customized plan based on each patient&rsquo;s symptoms and severity and can include options such as acetylcholinesterase inhibitors, immunosuppressives, immunoglobulin, eculizumab, thymectomy, or plasma exchange, with a goal of achieving and maintaining remission while minimizing adverse effects. This activity will provide a review and update of MG treatment options and include video clips highlighting key counseling pearls for specialty pharmacists. 
 
<img alt="acpe" src="https://s3.amazonaws.com/ptce/_media/_image/MG_video_thumb.png
" style="max-width:460px" /> 
 
Target audience:&nbsp;Specialty pharmacists 
Type of activity:&nbsp;Application 
Release date: September 8, 2020 
Expiration date: September 8, 2021 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Identify the symptoms and burden of myasthenia gravis (MG)</li>
	<li>Examine the safety and efficacy data of available treatment options for the management of MG</li>
	<li>Explore specialty pharmacy practices that have the potential to improve outcomes for patients with MG</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-265-H01-P. The activity is available for CE credit through September 8, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Leslie A. Hamilton, PharmD, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times Continuing Education&trade; Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa, PharmD, BCPS; Kelly McCormick; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose. 
 
Medical Writing Support for Counseling Vignettes: Jill E. Allen, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Continuing Education